Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
Status:
Completed
Trial end date:
2020-07-27
Target enrollment:
Participant gender:
Summary
This is an open label, non randomized, uncontrolled, multicenter, single arm observational
study. In this study, the enrolled subjects will be treated with Rebif human serum albumin
(HSA)-free formulation (with or without RebiSmart) 44 microgram (mcg), subcutaneous (sc),
thrice in a week (tiw) for 24 months.